Teneligliptin Hydrobromidum Intermedium CAS 401564-36-1 Puritas >99.5% (HPLC) Factory
Copia Teneligliptin Hydrobromide Related media Cum High Munditia
Teneligliptin Hydrobromide CAS 906093-29-6
1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazinum CAS 401566-79-8
Teneligliptin Hydrobromide Intermediate CAS 401564-36-1
| Nomen chemicum | (2S) -4-Oxo-2-(3-thiazolidinylcarbonyl) -1-pyrrolidinecarboxylicum acidum tert-butyl ester |
| Synonyma | (S)-tert-Butyl 4-oxo-2-(thiazolidine-3-carbonyl)pyrrolidine-1-carboxylata;3-((S)-1-tert-butoxycarbonyl-4-oxo-2-pyrrolidinylcarbonyl)-1,3-thiazolidine;(2S) -4-oxo-2-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidine-1-carboxylato;Teneligptin Intermedia B |
| CAS Number | 401564-36-1 |
| CATTUS Number | RF-1818 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C13H20N2O4S |
| M. Pondus | 300.37 |
| Density | 1.305 |
| Brand | Ruifu Chemical |
| Item | Inspectio Standard | Proventus |
| Aspectus | Alba ad lactis solidus | Conformare |
| Lepidium sativum | IR;HPLC RT | Conformare |
| Damnum in Siccatio | <1.00% | 0.20% |
| Substantiae cognatae | Quaelibet immunitas <0.50% | 0.24% |
| Totalis immunditiae <0.50% | 0.39% | |
| Assay | 99.5%~ 102.0% (In Siccata Basis) | 99.8% |
| Puritas Enantiomeric | >99.5% | 99.9% |
| Cinere sulphated | <0.20% | 0.02% |
| Test Standard | Enterprise Standard | |
| Consuetudinem | Intermedia de Teneligliptin Hydrobromide (CAS: 906093-29-6) | |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
(2S) -4-Oxo-2-(3-thiazolidinylcarbonyl) -1-pyrrolidinecarboxylicum acidum tert-butyl ester (CAS: 401564-36-1), media adhibenda ad parandum dipeptidylum peptidase IV (DPP-IV) inhibitor, intermedius. de Teneligliptin Hydrobromide (CAS: 906093-29-6).Teneligliptin est inhibitor DPP-4, qui in Iaponia anno 2012 probatus est ad tractationem speciei II diabete.Inventa et evoluta a Mitsubishi Tanabe Pharma sub artis nomine Tenelia®.Similia aliis inhibitoribus venalibus DPP-4, Teneligliptin in omnibus studiis bene toleratum fuit et QD dosing actionem inhibendi contra DPP-4 produxit diuturnam et incrementum in gradus activorum GLP-1, cum infimae rates excretionis renalis.
